Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report

- McGuire, Helen M., Shklovskaya, Elena, Edwards, Jarem, Trevillian, Paul R., McCaughan, Geoffrey W., Bertolino, Patrick, McKenzie, Catriona, Gourlay, Ralph, Gallagher, Stuart J., Fazekas de St. Groth, Barbara, Hersey, Peter

Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis

- Lomax, Anna J., McGuire, Helen M., Gupta, Sandeep K., Hollingsworth, Jane, Kim, Haewon, Fazekas de St Groth, Barbara, McGill, Neil, McNeil, Catriona, Choi, Clara J., Hersey, Peter, Karikios, Deme, Shannon, Kerwin, van Hal, Sebastian, Carr, Urszula, Crotty, Anne

Association of pembrolizumab with tumor response and survival among patients with advanced melanoma

- Ribas, Antoni, Hamid, Omid, Gangadhar, Tara C., Hersey, Peter, Dronca, Roxana, Joseph, Richard W., Zarour, Hassane, Chmielowski, Bartosz, Lawrence, Donald P., Algazi, Alain, Rizvi, Naiyer A., Hoffner, Brianna, Daud, Adil, Mateus, Christine, Gergich, Kevin, Lindia, Jill A., Giannotti, Maxine, Li, Xiaoyun Nicole, Ebbinghaus, Scott, Kang, S. Peter, Robert, Caroline, Hodi, F. Stephen, Wolchok, Jedd D., Kefford, Richard, Joshua, Anthony M., Patnaik, Amita, Hwu, Wen-Jen, Weber, Jeffrey S.

Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab

- Hodi, F. Stephen, Hwu, Wen-Jen, Joshua, Anthony M., Hersey, Peter, Dronca, Roxana, Joseph, Richard, Hille, Darcy, Xue, Dahai, Li, Xiaoyun Nicole, Kang, S. Peter, Ebbinghaus, Scot, Perrone, Andrea, Kefford, Richard, Wolchok, Jedd D., Weber, Jeffrey S., Daud, Adil, Hamid, Omid, Patnaik, Amita, Ribas, Antoni, Robert, Caroline, Gangadhar, Tara C.

EZH2 as a mediator of treatment resistance in melanoma

- Tiffen, Jessamy C., Gallagher, Stuart J., Tseng, Hsin-Yi, Filipp, Fabian V., Fazekas de St Groth, Barbara, Hersey, Peter

Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma

- Daud, Adil I, Wolchok, Jedd D., Joseph, Richard, Gangadhar, Tara C., Dronca, Roxana, Patnaik, Amita, Zarour, Hassane, Roach, Charlotte, Toland, Grant, Lunceford, Jared K., Li, Xiaoyun Nicole, Emancipator, Kenneth, Robert, Caroline, Dolled-Filhart, Marisa, Kang, S. Peter, Ebbinghaus, Scot, Hamid, Omid, Hwu, Wen-Jen, Weber, Jeffrey S., Ribas, Antoni, Hodi, F. Stephen, Joshua, Anthony M., Kefford, Richard, Hersey, Peter

Somatic copy number amplification and hyperactivating somatic mutations of EZH2 correlate with DNA methylation and drive epigenetic silencing of genes involved in tumor suppression and immune responses in melanoma

- Tiffen, Jessamy, Wilson, Stephen, Gallagher, Stuart J., Hersey, Peter, Filipp, Fabian V.

Melanoma early detection and awareness: how countries developing melanoma awareness programs could benefit from melanoma-proficient countries

- Wainstein, Alberto, Algarra, Salvador Martin, Whitaker, Dagmar, Quirt, Ian, Hauschild, Axel, Rutkowski, Piotr, Bastholt, Lars, Cinat, Gabriela, Demidov, Lev, Grob, Jean Jacques, Guo, Jun, Hersey, Peter, Espinosa, Enrique, Schachter, Jacob

Side effects and toxicities of targeted therapies in stage IV melanoma

- Ascierto, Paolo A., Bastholt, Lars, Hersey, Peter, Cinat, Gabriela, Eggermont, Alexander M. M., Hauschild, Axel, Espinosa, Enrique, Robert, Caroline

Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in metastatic melanoma

- Oliveira, Camila S., de Bock, Charles E., Molloy, Timothy J., Sadeqzadeh, Elham, Geng, Xin Yan, Hersey, Peter, Zhang, Xu Dong, Thorne, Rick F.

Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress

- Croft, Amanda, Tay, Kwang H., Zhang, Xu D., Boyd, Suzanah C., Guo, Su T., Jiang, Chen C., Lai, Fritz, Tseng, Hsin-Yi, Jin, Lei, Rizos, Helen, Hersey, Peter

OBATOCLAX and ABT-737 induce ER stress responses in human melanoma cells that limit induction of apoptosis

- Wroblewski, David, Jiang, Chen Chen, Croft, Amanda, Farrelly, Margaret L., Zhang, Xu Dong, Hersey, Peter

Pharmacodynamic effects and mechanisms of resistance to Vemurafenib in patients with metastatic melanoma

- Trunzer, Kerstin, Pavlick, Anna C., Hersey, Peter, Long, Georgina V., Lawrence, Donald, Ott, Patrick A., Amaravadi, Ravi K., Lewis, Karl D., Puzanov, Igor, Lo, Roger S., Koehler, Astrid, Kockx, Mark, Schuchter, Lynn, Spleiss, Olivia, Schell-Steven, Annette, Gilbert, Houston N., Cockey, Louise, Bollag, Gideon, Lee, Richard J., Joe, Andrew K., Sosman, Jeffrey A., Ribas, Antoni, Gonzalez, Rene, McArthur, Grant A., Hutson, Thomas E., Moschos, Stergios J., Flaherty, Keith T., Kim, Kevin B., Weber, Jeffrey S.

PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma

- Ye, Yan, Jin, Lei, Tay, Kwang Hong, Tseng, Hsin-Yi, Guo, Su Tang, de Bock, Charles E., Jiang, Chen Chen, Wang, Chun Yang, Wu, Mian, Zhang, Lie Jie, Hersey, Peter, Scolyer, Richard A., Wilmott, James S., Zhang, Xu Dong, Hu, Wang Lai, Yosufi, Benafsha, Thorne, Rick F., Liu, Tao, Rizos, Helen, Yan, Xu Guang, Dong, Li

Regulators of global genome repair do not respond to DNA damaging therapy but correlate with survival in melanoma

- Bowden, Nikola A., Ashton, Katie A., Scott, Rodney J., Vilain, Ricardo E., Avery-Kiejda, Kelly A., Davey, Ryan J., Murray, Heather C., Budden, Timothy, Braye, Stephen G., Zhang, Xu Dong, Hersey, Peter

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma

- Hamid, Omid, Robert, Caroline, Dronca, Roxana, Gangadhar, Tara C., Patnaik, Amita, Zarour, Hassane, Joshua, Anthony M., Gergich, Kevin, Elassaiss-Schaap, Jeroen, Algazi, Alain, Mateus, Christine, Boasberg, Peter, Daud, Adil, Tumeh, Paul C., Chmielowski, Bartosz, Ebbinghaus, Scot W., Li, Xiaoyun Nicole, Kang, S. Peter, Ribas, Antoni, Hodi, F. Stephen, Hwu, Wen-Jen, Kefford, Richard, Wolchok, Jedd D., Hersey, Peter, Joseph, Richard W., Weber, Jeffrey S.

The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance

- Wroblewski, David, Mijatov, Branka, Mohana-Kumaran, Nethia, Lai, Fritz, Gallagher, Stuart J., Haass, Nikolas K., Zhang, Xu Dong, Hersey, Peter

Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors

- Lai, Fritz, Jiang, Chen Chen, Farrelly, Margaret L., Zhang, Xu Dong, Hersey, Peter

Histone deacetylases (HDACs) as mediators of resistance to apoptosis in melanoma and as targets for combination therapy with selective BRAF inhibitors

- Lai, Fritz, Jin, Lei, Gallagher, Stuart, Mijatov, Branka, Zhang, Xu Dong, Hersey, Peter

Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737

- Lucas, Keryn M., Mohana-Kumaran, Nethia, Lau, Diana, Zhang, Xu Dong, Hersey, Peter, Huang, David C., Weninger, Wolfgang, Haass, Nikolas K., Allen, John D.